Skip to content

    Laxmi Dental

    LAXMIDENTL
    Healthcare·22 May 2026
    Management Summary

    Laxmi Dental delivered a strong Q4 FY26, with revenue growing 22% YoY to ₹74 crores and EBITDA expanding to 18.3%. The company maintained a debt-free status with healthy liquidity. Key drivers included robust performance in the dental lab business and strategic advancements in digital dentistry, including the launch of iScope 360. Despite external headwinds like tariffs and competition, the company achieved 16.2% YoY revenue growth for the full fiscal year.

    Highlights

    5
    • Q4 FY26 Revenue from operations of ₹74 crores, up 22% YoY.

    • Q4 FY26 Gross profit margin of 70.5%, a minor sequential improvement.

    • Q4 FY26 EBITDA of ₹13.5 crores, up 41.8% YoY, with EBITDA margins expanding to 18.3%.

    • FY26 Revenue from operations of ₹277.9 crores, a growth of 16.2% YoY.

    • Company remains debt-free with ₹99 crores in cash and bank balance including investments.

    Concerns

    4
    • US tariff impact weighed on EBITDA margin by around 74 bps in Q4 FY26, though the situation is now better at 10%.

    • Intensifying competition in the domestic aligner segment was a challenge during FY26.

    • Higher freight costs in March led to some delays in Vedia's international orders.

    • Challenges from labor code transitions and evolving microeconomics/geopolitical landscape during FY26.

    Key financials

    Metrics

    10

    Periods

    2

    Q4

    6
    • Revenue from Operations
      ₹74 Cr
      YoY+21.9%
    • Gross Profit
      ₹52.1 Cr
      YoY+9.1%
    • Gross Margin
      70.5%
    • EBITDA
      ₹13.5 Cr
      YoY+41.8%
    • EBITDA Margin
      18.3%

    FY26

    4
    • Revenue from Operations
      ₹277.9 Cr
      YoY+16.2%
    • EBITDA
      ₹43.4 Cr
    • PAT
      ₹28.9 Cr
    • PAT Margin
      10.4%

    Segment breakdown

    Q4 RevenueQ4 YoY Growth
    Dental Lab Business₹45.9 Cr27%
    International Lab Business40.9%
    Domestic Lab Business₹23.7 Cr16.3%
    Aligner Solutions - Bizdent10.9%
    Aligner Solutions - Vedia₹7.3 Cr
    Pediatric Dental Business - Kids-e-Dental₹5.4 Cr
    Heatmap· 2 shared metrics

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹18.4 crores

    Debt

    Debt disclosed

    Liquidity

    Cash ₹99 crores

    Guidance & targets

    5
    CategoryTargetPriority
    Market Share
    Digital penetration in domestic lab business
    over 90%
    High
    Growth
    Material business expansion
    good results
    Medium
    Growth
    Overall growth trajectory
    similar trajectory
    Medium
    Growth
    US business performance
    keep doing well
    Medium
    Profitability
    Margins
    do better
    Medium

    Digital penetration in domestic lab business

    medium-term
    Current80%
    Target>90%

    Why it matters

    Key driver for core dental business growth, efficiency, and long-term revenue.

    Now, our digital penetration in the domestic lab business stands at around 80% and we are targeting over 90% digital penetration over the medium-term.

    How to verify

    guidance_and_targets[category='Market Share'][metric='Digital penetration in domestic lab business']

    Risks & concerns

    5
    RiskSeverity

    US tariff volatility

    Weighed on EBITDA margin by 74 bps in Q4 FY26, though the situation is now better at 10% tariff on US exports.Management acknowledged

    medium

    Intensifying competition in domestic aligner segment

    Mentioned as a challenge during FY26, company focuses on margin preservation and digital innovation.Management acknowledged

    medium

    Labor code transitions

    Mentioned as an external headwind during FY26.Management acknowledged

    medium

    Evolving microeconomics and geopolitical landscape

    Company remains vigilant and responsive to these external headwinds during FY26.Management acknowledged

    medium

    Higher freight costs

    Freight costs doubled or tripled in March, causing some Vedia international shipments to be delayed in Q4 FY26.Management acknowledged

    medium

    Q&A highlights

    8

    “Bizdent is purely domestic and Vedia, it is a raw metal business where minor percentage is India, but majority of the percentage is international. ... we wanted on our side as management to preserve the margins. And I think we have done that. That is what it shows. And like you said, we have seen recovery back in Q4.”

    Clarifies the geographical split of aligner segments and management's strategy to prioritize margins over volume growth for Bizdent, explaining Q4 recovery.

    asked by Ajay (Niveshaay)

    2 min read6 chapters

    Detailed Narrative

    01

    Q4 FY26 Performance Overview

    Laxmi Dental reported a strong Q4 FY26, with revenue from operations reaching ₹74 crores, a 22% year-on-year growth compared to ₹60.7 crores last year. Gross profit margin stood at a healthy 70.5%, showing a minor sequential improvement. EBITDA increased by 41.8% year-on-year to ₹13.5 crores, with margins expanding to 18.3% from 15.7% in the prior year. For the full fiscal year FY26, the company achieved ₹277.9 crores in revenue, growing 16.2% over the previous year's ₹239.1 crores, with a PAT margin of 10.4%.

    02

    Segmental Business Growth

    The dental lab business achieved its highest-ever quarterly revenue of ₹45.9 crores, growing 27% YoY, driven by robust international operations (40.9% YoY growth) and solid domestic business growth (16.3% YoY, reaching ₹23.7 crores). The aligner solutions business saw Bizdent, the clear aligner segment in India, grow 10.9% YoY. Vedia, the aligner raw metal business, reported ₹7.3 crores in revenue, though some international orders were delayed due to higher freight costs in March. The pediatric dental business, Kids-e-Dental, contributed ₹5.4 crores in Q4.

    03

    Digital Dentistry and iScope 360 Launch

    Laxmi Dental is actively pursuing its digital dentistry mission, with digital penetration in the domestic lab business currently at 80%, targeting over 90% in the medium-term. The company launched iScope 360, an AI-connected remote dental platform, enabling remote scanning, real-time monitoring, and virtual consultations. The revenue model for iScope 360 involves selling the scope (retailed at approximately ₹2000) and subsequent subscription points for various services, primarily driven by dentists, complementing the scanner business.

    04

    Margins and Cost Structure

    The company achieved healthy Q4 FY26 EBITDA and PAT margins of 18.3% and 13.6% respectively, despite a 74 bps impact on EBITDA from US tariffs. Employee costs for the quarter were ₹26.8 crores, remaining stable sequentially. Management emphasized its commitment to maintaining stable margins and improving operational efficiencies through automation and digital dentistry, expecting operational leverage as the business grows.

    05

    Capital Allocation and Liquidity

    Laxmi Dental reported a CAPEX of ₹18.4 crores for FY26, utilizing IPO proceeds for strategic investments. The company maintains a strong financial position, remaining debt-free. Its cash and bank balance, including investments, stood at ₹99 crores, providing ample liquidity for future growth initiatives and operational flexibility.

    06

    Outlook and Growth Drivers

    Management expressed confidence in sustained growth over the next two to three years, aiming to expand its material business into multiple countries and improve overall margins. The US business is expected to continue performing well, with the tariff situation improving. The company's strategy against intensifying competition, particularly in the domestic aligner segment, focuses on leveraging digital automation and innovation to maintain market share and profitability.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.